Travere Therapeutics officer proposes $304K share sale
The proposed sale is a mandatory sell-to-cover transaction for tax withholding, not a discretionary trade by the officer.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Travere Therapeutics, Inc. (TVTX) lists a proposed sale by Officer Christopher Cline of 7,239 common shares, with an aggregate market value of $303,522.27, on approximately April 14, 2026.
Cline acquired the shares from the issuer on April 13, 2026, through performance restricted stock unit vesting as compensation. The sale is a mandatory “sell to cover” transaction under the issuer’s election under its equity incentive plans to fund tax withholding; the remarks state that it is not discretionary. Travere reported 92,241,550 common shares outstanding.
Key Figures
Key Terms
sell to cover financial
Performance Restricted Stock Unit Vesting financial
tax withholding obligation financial
equity incentive plans financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.